Spots Global Cancer Trial Database for Apatinib Plus Docetaxel in Advanced Non-squamous Non-small Cell Lung Cancer(NSCLC)
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Apatinib Plus Docetaxel in Advanced Non-squamous Non-small Cell Lung Cancer(NSCLC)
Official Title: A Study of Combined Treatment of Apatinib With Docetaxel as Post Second-line Therapy in Advanced Non-squamous Non-small Cell Lung Cancer(NSCLC)
Study ID: NCT03416231
Conditions
Study Description
Brief Summary: The purpose of this study was to evaluate the effectiveness and safety of apatinib combined with docetaxel in NSCLC.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Affiliated Hospital of North Sichuan Medical College, Nanchong, Sichuan, China
Contact Details
Name: Daiyuan Ma, M.D
Affiliation: Affiliated Hospital of North Sichuan Medical College
Role: PRINCIPAL_INVESTIGATOR
Name: xin hu, M.D.
Affiliation: Nanchong Central Hospital
Role: STUDY_DIRECTOR
Name: xiangdong fang, M.d.
Affiliation: Dazhou Central Hospital
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
